Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who fully understand what the study involves and are willing to sign a consent form
• People who have been diagnosed with non-Hodgkin lymphoma (NHL), acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), or myelodysplastic syndrome (MDS)
• People whose general physical functioning meets a certain minimum level, as measured by a standard medical scale (confirm with trial site)
• People whose bone marrow, blood clotting, liver, and kidney function are at adequate levels (confirm with trial site)
• People whose cancer is considered high-risk for a complication called Tumour Lysis Syndrome, as agreed between the investigator and study sponsor
• People whose disease measurements meet certain study requirements (confirm with trial site)
• People whose expected survival is at least 12 weeks
• People of childbearing potential who agree to use a highly effective form of contraception from signing the consent form until at least 3 months after the last study dose, and who have had a negative pregnancy test within 7 days before the first dose

Who may not be able to join:

• People who have previously been treated with a BCL-2 inhibitor, unless that treatment was stopped due to intolerability
• People with NHL who have been diagnosed with Burkitt's lymphoma, lymphoblastoid lymphoma/leukaemia, or a condition called post-transplant lymphoproliferative disease (PTLD)
• People with AML who have a specific subtype called acute promyelocytic leukaemia, or who have a Philadelphia chromosome-positive diagnosis, or persistent leukaemia outside the bone marrow
• People whose cancer has spread to the central nervous system (brain or spinal cord)
• People who have had a donor stem cell transplant at any time, or a stem cell transplant using their own cells within the past 3 months
• People who have received a vaccine within 4 weeks before the first dose, or who are scheduled to receive a vaccine during the study
• People who test positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, or HIV antibody
• People who have received certain anti-cancer antibody treatments within 4 weeks before the first dose, participated in another interventional drug trial within 4 weeks, or received CAR-T therapy within 12 weeks before the first dose (confirm with trial site, as the source criteria appear incomplete)
• People who have received anti-cancer or investigational treatment within 14 days before the first dose, or who have not recovered from significant side effects of previous treatment
• People who have taken steroid-based anti-cancer therapy, or certain medications that affect a liver enzyme called CYP3A, within 7 days before the first dose
• People who have eaten grapefruit, grapefruit products, Seville oranges (including certain marmalades), or starfruit within 3 days before the first dose
• People with poorly controlled high blood pressure, reduced heart pumping function, an abnormal heart rhythm, severe heart failure, a heart attack or bypass surgery within the past 6 months, a blood clot event within the past 6 months, or other significant heart conditions the investigator considers unsuitable
• People with a history of serious kidney, nerve, psychiatric, lung, hormonal, immune, heart, or liver conditions that the investigator believes could affect their safety or participation
• People who have had another active cancer (other than NHL, AML, or MDS) within the 3 years before joining the study
• People who have difficulty swallowing or absorbing oral medications
• People with other significant uncontrolled medical conditions
• People who, in the investigator's judgement, have any other medical, personal, or practical factors that could affect study results or make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.